Fear of Pain in Patients With Advanced Cancer or in Patients With Chronic Noncancer Pain

LeMay, Katerine; Wilson, Keith G.; Buenger, Usha; Jarvis, Virginia; Fitzgibbon, Edward; Bhimji, Khadija; Dobkin, Patricia L.

doi:10.1097/ajp.0b013e3181f3f667

Cited by 54 publications

(34 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, pain is a symptom commonly reported as most significant among patients with ABC [16] and has been shown to be a strong predictor of overall HRQoL [26]. In particular, pain is a symptom commonly reported as most significant among patients with ABC [16] and has been shown to be a strong predictor of overall HRQoL [26].…”

Section: Discussionmentioning

confidence: 99%

“…These combination therapies have also been associated with higher response rates, but additional treatment-related toxicities could negatively impact health-related quality of life (HRQoL) [13]. Given the palliative nature of ABC treatment, consideration of treatment choices that minimize the impact to HRQoL is important in guiding treatment decisions [14][15][16][17]. Thus, it is now recommended that patient-reported HRQoL be considered alongside efficacy and safety to better understand the impact of treatment [10,14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy.

Kaufman

Toi

Neven³

et al. 2018

JCO

View full text Add to dashboard Cite

Background In the phase III MONARCH 2 study (NCT02107703), abemaciclib plus fulvestrant significantly improved progression‐free survival (PFS) versus placebo plus fulvestrant in patients with hormone receptor‐positive (HR+), HER2‐negative advanced breast cancer (ABC). This study assessed patient‐reported pain, global health‐related quality of life (HRQoL), functioning, and symptoms. Materials and Methods Abemaciclib or placebo (150 p.o. mg twice daily) plus fulvestrant (500 mg, per label) were randomly assigned (2:1). The modified Brief Pain Inventory, Short Form (mBPI‐sf); European Organization for Research and Treatment of Cancer (EORTC) QoL Core 30 (QLQ‐C30); and Breast Cancer Questionnaire (QLQ‐BR23) assessed outcomes. Data were collected at baseline, cycle 2, every two cycles 3–13, thereafter at every three cycles, and 30 days postdiscontinuation. Longitudinal mixed regression and Cox proportional hazards models assessed postbaseline change and time to sustained deterioration (TTSD) by study arm. Results On‐treatment HRQoL scores were consistently maintained from baseline and similar between arms. Patients in the abemaciclib arm (n = 446) experienced a 4.9‐month delay in pain deterioration (mBPI‐sf), compared with the control arm (n = 223), and significantly greater TTSD on the mBPI‐sf and analgesic use (hazard ratio, 0.76; 95% CI, 0.59–0.98) and QLQ‐C30 pain item (hazard ratio, 0.62; 95% CI, 0.48–0.79). TTSD for functioning and most symptoms significantly favored the abemaciclib arm, including fatigue, nausea and vomiting, and cognitive and social functioning. Only diarrhea significantly favored the control arm (hazard ratio, 1.60; 95% CI, 1.20–2.10). Conclusion HRQoL was maintained on abemaciclib plus fulvestrant. Alongside superior PFS and manageable safety profile, results support treatment with abemaciclib plus fulvestrant in a population of patients with endocrine‐resistant HR+, HER2‐negative ABC. Implications for Practice In MONARCH 2, abemaciclib plus fulvestrant demonstrated superior efficacy and a manageable safety profile for patients with in hormone receptor‐positive (HR+), HER2‐negative (−) advanced breast cancer (ABC). Impact on health‐related quality of life (HRQoL) is important to consider, given the palliative nature of ABC treatment. In this study, abemaciclib plus fulvestrant, compared with placebo plus fulvestrant, significantly delayed sustained deterioration of pain and other patient‐reported symptoms (including fatigue, nausea, vomiting), and social and cognitive functioning. Combined with demonstrated clinical benefit and tolerability, the stabilization of patient‐reported symptoms and HRQoL further supports abemaciclib plus fulvestrant as a desirable treatment option in endocrine resistant, HR+, HER2− ABC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy.

Kaufman

Toi

Neven³

et al. 2018

JCO

View full text Add to dashboard Cite

show abstract

“…This finding is important because the liver may be perceived as a relatively silent organ that does not cause pain. Pain is one of the most feared symptoms by patients, if not the most feared (Lemay et al, 2011). …”

Section: Introductionmentioning

confidence: 99%

Symptom Distress in Patients With End-Stage Liver Disease Toward the End of Life

Hansen

Leo

Chang

et al. 2015

Gastroenterology Nursing

View full text Add to dashboard Cite

“…In fact, whilst most of the participants expressed shock and fear on receiving a diagnosis, one participant (Maria) expressed relief as this provided her with a label for the physical pain that she had been experiencing for several months. This should be further interpreted in a context where patients with cancer fear physical pain to a great extent (Lemay et al., ; Strang, ). Additionally, undergoing chemotherapy was perceived by Maria as a means to target the physical pain which she could not withstand.…”

Section: Discussionmentioning

confidence: 99%

Being diagnosed with cancer: The experiences of patients with non‐Hodgkin's lymphoma

Chircop¹,

Scerri

2017

Journal of Clinical Nursing

View full text Add to dashboard Cite

show abstract

Fear of Pain in Patients With Advanced Cancer or in Patients With Chronic Noncancer Pain

Abstract: the findings emphasize the importance of psychological dimensions of pain in patients with advanced cancer, as well as the similarities and differences between the 2 groups of patients suffering from chronic pain.

Cited by 54 publications

References 49 publications

Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy.

Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2- advanced breast cancer (ABC) who progressed on endocrine therapy.

Symptom Distress in Patients With End-Stage Liver Disease Toward the End of Life

Being diagnosed with cancer: The experiences of patients with non‐Hodgkin's lymphoma

Contact Info

Product

Resources

About